Rituximab Therapy for Severe Refractory Chronic Henoch-Schönlein Purpura

To report on the efficacy of rituximab (RTX) therapy in standard treatment–refractory, chronic Henoch-Schönlein purpura, a retrospective chart review of 3 pediatric patients treated with RTX for severe refractory chronic Henoch-Schönlein purpura was performed. All 3 patients responded to 1 or 2 courses of RTX without serious adverse events.